Solid organ transplant recipients have an elevated incidence of thyroid cancer. We evaluated a wide range of potential risk factors in a cohort of 229 300 U.S. solid organ transplant recipients linked with 15 stage/regional cancer registries . Incidence rate ratios (IRRs) were adjusted for age, sex, race/ethnicity, transplanted organ, year of transplantation, and time since transplantation. Hazard ratios (HRs) for death and/or graft failure were adjusted for age, sex, race/ethnicity, transplanted organ, and year of transplantation. After transplantation, 356 thyroid cancers were diagnosed. Thyroid cancer incidence was 2.50-fold higher in transplant recipients than the general population (95% confidence interval [CI] 2.25-2.77). Among recipients of different organs, kidney recipients had the highest incidence of thyroid cancer (IRR = 1.26, 95% CI 1.03-1.53). Elevated thyroid cancer incidence was associated with cholestatic liver disease/cirrhosis as an indication for liver transplantation (IRR = 1.69, 95% CI 1.09-2.63), hypertensive nephrosclerosis as an indication for kidney transplantation (IRR = 1.41, 95% CI 1.03-1.94), and longer prior dialysis among kidney recipients (5+ vs. <1 year, IRR = 1.92, 95% CI 1.32-2.80; p-trend <0.01). Posttransplantation diagnosis of thyroid cancer was associated with modestly increased risk of death (HR = 1.33, 95% CI 1.02-1.73). Overall, our results suggest that end-stage organ disease and longer duration of dialysis may contribute to higher thyroid cancer incidence in transplant recipients.
Introduction
Thyroid cancer incidence has increased in many parts of the world over the past several decades (1) . This trend is largely attributable to a rise in papillary thyroid cancer (PTC), the most common histologic type. Greater incidental detection of small (<1 cm), indolent PTCs through more widespread use of ultrasonography and other imaging modalities may account for much of this increase (2) . However, the incidence of large (>5 cm) PTCs has increased at nearly the same rate, suggesting that there also is a true increase in thyroid cancer due to greater exposure to environmental risk factors (3) . Nonetheless, the etiology of thyroid cancer remains poorly understood, and few risk factors have been identified apart from female sex, exposure to ionizing radiation, particularly at young ages, and excess body weight (4-6).
Solid organ transplant recipients have an increased incidence of thyroid cancer compared with the general population, according to most (7) (8) (9) , but not all (10) , studies on the topic, but the reasons for any excess have not been evaluated. Among transplant recipients, the higher incidence of some cancers, particularly those that are virus related, is attributable to immunosuppression that results from medications used to prevent graft rejection. However, immunosuppression does not play an obvious role in thyroid cancer development. For instance, thyroid cancer does not arise in excess in people with human immunodeficiency virus (HIV) infection, another immunosuppressed population (11) .
The increased thyroid cancer incidence in transplant recipients could be at least partially attributable to heightened medical surveillance (7) (8) (9) . Compared with the general population, transplant recipients have much greater engagement with the medical care system, including frequent clinical evaluations that could involve thyroid palpation or diagnostic imaging of the head, neck, and chest. Evaluation of endocrine abnormalities in transplant recipients could also lead to incidental detection of thyroid cancer. Overdiagnosis might be expected to manifest as increased thyroid cancer incidence in the few months after organ transplantation, when transplant recipients are under closest medical evaluation but would be less of a factor over the long term. A longer-term increase in incidence after organ transplantation could, on the other hand, result from factors that promote thyroid cancer development and progression. Overdiagnosis would also be associated with elevated incidence of early-stage thyroid cancers but could not explain any excess in metastatic cases. Exposures that are unique to the transplant population include the use of immunosuppressant medications, which could have direct carcinogenic effects (12) or could indirectly, via immunosuppression, promote the development of undiagnosed thyroid cancer at transplantation. In addition, certain underlying medical conditions, are more prevalent among transplant recipients and may also contribute to an increased risk of thyroid cancer. End-stage renal disease (ESRD), present in all kidney recipients, has been linked to an elevated risk of thyroid cancer (13) (14) (15) . However, to date, the evidence regarding a possible association of these factors with thyroid cancer risk in transplant recipients is limited.
An understanding of the epidemiology of thyroid cancer among transplant recipients will help clarify the etiology of this malignancy and provide information to help clinicians improve outcomes in this high-risk population. Using registry data from a large U.S. population of solid organ transplant recipients linked with multiple cancer registries, we assessed thyroid cancer incidence in transplant recipients and evaluated a wide range of potential risk factors, including demographic factors, transplant characteristics, immunosuppressant medications, medical indication for organ transplantation, and, among kidney recipients, duration of prior dialysis.
Methods
The Transplant Cancer Match Study links the Scientific Registry of Transplant Recipients (SRTR), a nationwide registry of all U.S. transplantations, with 15 population-based cancer registries (7) . The resulting cohort includes 45% of the U. Utah (1987 Utah ( -2008 , and the metropolitan area of Seattle, Washington (1987 Washington ( -2008 . We restricted the study to individuals of the major race/ethnicity groups (non-Hispanic white, nonHispanic black, Hispanic, and Asian/Pacific Islander) to allow comparisons with general population cancer rates. The Transplant Cancer Match Study was approved by human subjects' research review committees at the National Cancer Institute and, as required, participating cancer registries.
Follow-up for transplant recipients began at transplantation or the start of cancer registry coverage, whichever came later, and ended at thyroid cancer diagnosis, death, transplant failure, retransplantation, loss to follow-up, or end of cancer registry coverage, whichever came first. Person-time was apportioned separately for each transplantation for people who received multiple successive transplants. We obtained information on potential thyroid cancer risk factors from the SRTR. This included demographic characteristics (age at transplantation, sex, race/ethnicity), transplant characteristics (transplanted organ), medical conditions that are the indication for transplantation, induction and initial maintenance immunosuppressant medications (prescribed at the time of transplantation and initial hospital discharge, respectively), and among kidney recipients, duration of dialysis before transplantation.
We calculated standardized incidence ratios (SIRs) to compare thyroid cancer incidence in transplant recipients with incidence in the general U.S. population. SIRs were calculated as the number of observed thyroid cancer cases divided by the number expected based on general population rates specific to registry, 5-year age group, sex, race/ethnicity, and calendar period. We observed an especially high SIR in the first year after transplantation; in a sensitivity analysis, this period was excluded from SIR calculations and all internal risk comparisons to evaluate the potential impact of surveillance bias around the time of organ transplantation. We then estimated SIRs overall, according to histology or stage at diagnosis, and separately by sex, race/ethnicity, age at transplantation, calendar year of transplantation, and transplanted organ.
For internal comparisons among transplant recipients, we used Poisson regression to calculate incidence rate ratios (IRRs). We examined associations for thyroid cancer overall, PTC, local stage thyroid cancer, and regional/distant stage thyroid cancer. Attained age, sex, race/ethnicity, transplanted organ, time since transplantation, and year of transplantation were assessed in mutually adjusted models. These six factors were also included as adjustment factors in multivariable models that assessed associations of individual induction and maintenance medications prescribed at transplantation and initial hospital discharge, respectively, and, among patients receiving a particular organ, grouped medical conditions that were indications for transplantation. Associations with race/ethnicity, transplanted organ, and medical conditions were modeled using effect parameterization, which compares each category to the overall average. We also evaluated thyroid cancer incidence in relation to duration of dialysis before transplantation among kidney recipients. Other factors potentially related to immunosuppression in this population that were evaluated included pretransplantation history of diabetes (available for transplantations from 1995 on), body mass index, HLA mismatch, and, among kidney recipients, PRA.
As a sensitivity analysis, we restricted the analysis of immunosuppressant medications to transplantations occurring between 1998 and 2002, a transition period when most of these medications were overlapping in use. Because SIRs were highest in the first year after transplantation (see Results), which could reflect surveillance bias or delayed diagnosis of prevalent cases around the time of organ transplantation, in another sensitivity analysis we excluded the first year of follow-up.
Finally, we evaluated the association between thyroid cancer diagnosis after organ transplantation and subsequent risk of death and/or graft failure or retransplantation. For this analysis, we used Cox proportional hazards regression models adjusted for age at transplantation, sex, race/ ethnicity, transplanted organ, and year of transplantation. Diagnosis of thyroid cancer was treated as a time-dependent risk factor. Follow-up started on the date of transplantation or start of cancer registry coverage, whichever came later, and ended on the date of death, graft failure, retransplantation, loss to follow-up, or end of cancer registry coverage, whichever came first.
Results
We studied 229 300 individuals who received a total of 248 136 transplants. Median follow-up time was 3.9 years (interquartile range 1.4-7.4 years). Most transplantations occurred in patients who were male (61%), non-Hispanic white (61%), and aged 35-64 years (68%) ( Table 1) . Kidney transplantations were the most common (58%), followed by liver (22%), heart (10%), lung (4%), and other or multiple organs (6%). Most transplantations (91%) were first transplantations. Transplantations that were excluded from the study population, largely because the recipient's state of residence did not participate in the linkage with the transplant registry or the transplantation did not overlap with years of cancer registry coverage, were similar to those that were included by sex, age at transplantation, transplanted organ, and transplant number. Transplants that were excluded were more likely to have occurred in nonHispanic whites (69% vs. 61%), less likely to have occurred in Hispanics (7% vs. 16%) and Asian/Pacific Islanders (3% vs. 6%), and more likely to have occurred in the earliest and most recent calendar year periods (23% vs. 16% in 1987-1994, 22% vs. 7% in 2010-2012).
Thyroid cancer was diagnosed in 356 transplant recipients (incidence rate 29.2 per 100 000 person-years). The vast majority were PTCs (91%), while 5% were follicular, 2% were medullary, 1% were anaplastic, and 2% were other/unspecified types.
Thyroid cancer incidence was elevated 2.50-fold in these transplant recipients compared with the general population (95% CI 2.25-2.77) ( Table 2 ). SIRs were significantly elevated over the entire follow-up period, with the highest elevation occurring in the first year after transplantation (SIR for 0-0.49 years = 4.31, 95% CI 3.17-5.74; SIR for 0.5-0.99 years = 4.10, 95% CI 2.96-5.54), a nadir around 2.0-4.9 years after transplantation (SIR = 1.83, 95% CI 1.45-2.27), and a subsequent increase over time (5-9 years, SIR = 2.29, 95% CI 1.85-2.81; 10+ years, SIR = 2.43, 95% CI 1.76-3.27). A similar pattern was observed for PTC, local stage thyroid cancer, and regional/distant stage thyroid cancer ( Figure 1 ). SIRs were significantly elevated in men and women and for all racial/ ethnic groups. The highest SIRs were observed in recipients who underwent transplantation before age 20 (11 cases, SIR = 6.14, 95% CI 3.07-10.99), and SIRs declined with increasingly older age groups. By transplanted organ, the highest elevations were observed in kidney recipients and the lowest in liver recipients. By histology, incidence was significantly elevated for PTC and other/unspecified types but not for follicular, medullary, or anaplastic types. Incidence was elevated for local, regional, and unstaged cancer; the SIR was not increased for distant stage cancer (eight cases), but the CI was wide.
Among transplant recipients, overall thyroid cancer incidence increased significantly with greater attained age Recipients with other/unknown race/ethnicity were excluded from the study population to allow comparisons with general population cancer rates.
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American Journal of Transplantation 2017; 17: 2911-2921and was higher in women than in men (Table 3) . Compared with the average, non-Hispanic blacks had a lower incidence (IRR = 0.68, 95% CI 0.52-0.88), and no significant differences were observed for non-Hispanic whites, Hispanics, and Asian/Pacific Islanders. Compared with the average, kidney recipients had significantly higher thyroid cancer incidence (IRR = 1.26, 95% CI 1.03-1.53), liver recipients had lower incidence (IRR = 0.68, 95% CI 0.52-0.89), but no significant differences in incidence were observed for heart, lung, or other/multiple organ recipients. Thyroid cancer incidence was modestly increased with more recent calendar year of transplantation. Results according to age, sex, and organ type were similar after we restricted analysis to PTC or local stage thyroid cancers. For regional/distant (but not local) stage cancers, non-Hispanic blacks had lower incidence while Hispanics and Asian/Pacific Islanders had higher incidence compared with the average.
We next evaluated associations with specific immunosuppressant medications ( We also evaluated thyroid cancer incidence by medical indication for organ transplantation (Table 5) . Among kidney recipients, hypertensive nephrosclerosis as the indication for transplantation was associated with elevated thyroid cancer risk compared with the average (IRR = 1.41, 95% CI 1.03-1.94), while diabetes mellitus was associated with reduced risk (IRR = 0.78, 95% CI 0.56-1.09), particularly after restricting the outcome to PTC (IRR = 0.65, 95% CI 0.44-0.94). Among liver recipients, cholestatic liver disease/cirrhosis was associated with increased risk compared with the average (IRR = 1.69, 95% CI 1.09-2.63). The higher risk associated with cholestatic liver disease did not differ substantially when we separately considered the two major disease entities, primary sclerosing cholangitis and primary biliary cirrhosis. Specifically, compared with liver recipients without either condition, increased thyroid cancer risk was observed in those with primary sclerosing cholangitis (IRR = 1.74, 95% CI 0.61-4.92, based on n = 4 cases) or primary biliary cirrhosis (IRR = 2.62, 95% This category includes three cases of unspecified carcinoma (International Classification of Diseases for Oncology version 3 morphology code 8010), one mixed adenocarcinoma (8255), one papillotubular adenocarcinoma (8263), one insular carcinoma (8337), and one mucoepidermoid carcinoma (8430). CI 1.22-5.64, n = 10). There were too few cases to evaluate medical indications for transplantation among heart and lung recipients.
Among kidney recipients, greater duration of dialysis before transplantation was associated with increased thyroid cancer incidence (5+ vs. 0-<1 years, IRR = 1.92, 95% CI 1.32-2.80; p-trend <0.01; Table 6 ). Results were more pronounced when we restricted the outcome to regional/distant stage cancer (IRR = 4.01, 95% CI 1.98-8.11; p-trend <0.01).
Pretransplantation history of diabetes, body mass index, HLA mismatch, and, among kidney recipients, PRA were not clearly associated with thyroid cancer incidence (Table S1 ).
In a sensitivity analysis that excluded the first year of follow-up (Tables S2-S6 ), the main difference was the slightly attenuated SIRs for thyroid cancer overall (SIR = 2.20, 95% CI 1.94-2.48), by histology and stage at diagnosis, and for population subgroups (Table S2 ).
There were 51 667 deaths and 43 004 graft failures or retransplantations during follow-up. A diagnosis of thyroid cancer after organ transplantation was associated with modestly increased risks of death (hazard ratio [HR] = 1.33, 95% CI 1.02-1.73), graft failure or retransplantation (HR = 1.18, 95% CI 0.89-1.57), and the combined outcome of death, graft failure, or retransplantation (HR = 1.23, 95% CI 1.01-1.49).
Discussion
Solid organ transplant recipients are a high-risk population for thyroid cancer. As we observed previously in an overview of cancer risk in this cohort (7), incidence of thyroid cancer, including the most common histologic type (PTC), is elevated more than twofold among U.S. solid organ transplant recipients compared with the general population. In the present study, we evaluated a wide range of factors that could potentially explain this increase, including heightened medical surveillance, immunosuppressant medications, medical indications for transplantation, and, for kidney recipients, duration of prior dialysis.
Due to their engagement with the medical care system (8), we expected that transplant recipients would be more likely than the general population to undergo evaluation for thyroid nodules, which could lead to detection of thyroid cancer, particularly in the time immediately before and soon after the date of organ transplantation. Consistent with some degree of overdiagnosis, we observed much higher incidence of thyroid cancer in the first year of follow-up, particularly for local stage thyroid cancer, and the incidence declined thereafter. Nonetheless, thyroid cancer incidence rose again subsequently and remained significantly elevated above general population rates for more than 10 years after transplantation, and the pattern was similar for regional/distant thyroid cancer, indicating that overdiagnosis was not the entire explanation. Furthermore, the distribution of local, regional, distant, and unstaged thyroid cancers (68%, 26%, 3%, and 4%, respectively) in this patient population was similar to that of the general U.S. population (2006-2012) (4). Alternatively, the high incidence of thyroid cancer posttransplantation, particularly in the first year, may be attributable to a promotional influence of immunosuppression on thyroid cancers that were undiagnosed at the time of transplantation.
We hypothesized that etiologic factors would be more strongly associated with regional/distant stage thyroid cancer, whereas surveillance-related factors would be associated with local stage thyroid cancers, which are generally smaller than more advanced tumors and, thus, The p-value for heterogeneity was calculated using the likelihood ratio test for variables with more than two levels; the p-value for trend was calculated using the Wald test for categorical variables modeled ordinally. CI, confidence interval; IRR, incidence rate ratio.
Bolded values are statistically significant at p < 0.05. 1 IRRs for attained age, sex, race/ethnicity, transplanted organ, time since transplantation, and year of transplantation were mutually adjusted for each other. 2 The categories of attained age were 0-19, 20-34, 35-49, 50-64, 65+ years. 3 These variables were modeled using effect parameterization, which compares each category to the average of all of the categories. IRRs were adjusted for attained age, sex, race/ethnicity, transplanted organ, time since transplantation, and year of transplantation. IRRs were adjusted for attained age, sex, race/ethnicity, transplanted organ, time since transplantation, and year of transplantation and were modeled using effect parameterization, which compares each category to the average of all of the categories. more likely to be identified incidentally. The associations of regional/distant stage thyroid cancer with race/ ethnicity and duration of dialysis (among kidney recipients) suggest that these factors were unlikely to be explained by increased surveillance. Although the SIR for thyroid cancer was especially elevated in young transplant recipients, these cancers were rare, and thyroid cancer incidence increased with older age. Indeed, the associations with older age and female sex were present only for local stage cancer, perhaps mainly reflecting opportunity for early detection of thyroid cancer.
Kidney recipients had the highest incidence of thyroid cancer among recipients of different organs. Of note, the highest risk was observed for patients whose indication for kidney transplantation was hypertensive nephrosclerosis, which is a leading cause of ESRD. Other studies have demonstrated an elevated risk of thyroid cancer among ESRD patients on dialysis (13) (14) (15) . ESRD has been hypothesized to influence thyroid cancer development due to impaired DNA repair, reduced antioxidant defense, and accumulation of carcinogenic compounds resulting from reduced renal elimination (13) . Reduced kidney function and chronic kidney disease are also commonly associated with thyroid dysfunction, goiter, and nodules (17) (18) (19) , which have been hypothesized to play a direct role in thyroid cancer development (20) (21) (22) (23) (24) (25) (26) (27) . We cannot rule out the possibility that diagnostic workup of conditions that are prevalent in ESRD patients, including benign thyroid conditions and secondary hyperparathyroidism, could lead to incidental detection of thyroid cancer, but such workup would not be expected to lead to an association with regional/distant stage thyroid cancer. We previously reported that, among ESRD patients in the Transplant Cancer Match Study, a higher incidence of thyroid cancer was present during periods of dialysis than during transplantation intervals (when patients were receiving immunosuppressant medications) (28) . Similar findings were observed in a cohort of kidney transplant recipients in Australia and New Zealand (15, 29) . Here, we noted that risk of thyroid cancer, particularly regional/ distant stage cancer, was highest among kidney recipients with the greatest duration of dialysis before transplantation (5+ years). Thus, ESRD and factors associated with greater duration of dialysis appear to contribute to the increased risk of thyroid cancer among kidney recipients.
Nonetheless, it remains unclear whether transplant recipients would benefit from screening to allow for early detection of thyroid cancer. Thyroid cancer is typically associated with an excellent prognosis unless diagnosed at an advanced stage (4), and risks of thyroid cancer recurrence and thyroid cancer mortality (which reflects both cancer incidence and survival after diagnosis) have not appeared to be increased among solid organ transplant recipients (10, (30) (31) (32) (33) . There are substantial concerns about overdiagnosis and overtreatment of small Finally, individuals whose medical indication for liver transplantation was cholestatic liver disease/cirrhosis had a 69% increased incidence of thyroid cancer compared with the average; the risk was similarly elevated for PSC and PBC. This finding is unexplained as, to our knowledge, liver diseases are not a well-recognized risk factor for thyroid cancer. Thyroid cancer incidence was not especially increased among heart or lung recipients, who typically receive the most intensive immunosuppressive therapy. This finding, along with the absence of increased incidence among HIV-infected individuals (11), further supports that immunosuppression itself is not a strong risk factor for thyroid cancer.
Strengths of our study include the representative sample of transplant recipients, selected based on geographic coverage by cancer registries and including approximately 45% of all U.S. transplant recipients. Although there were some differences between transplantations that were included versus excluded from the study population (in large part due to the recipient's state of residence) in terms of race/ethnicity and calendar year of transplantation, these differences would not have affected the results shown here, and the two groups were otherwise similar. Cancer registry follow-up allowed nearly complete ascertainment of thyroid cancers for individuals who resided in participating states. We also had information on a wide range of demographic characteristics, indications for transplantation, and immunosuppressant medications. Information on stage at diagnosis allowed us to distinguish thyroid cancers according to aggressive potential.
Limitations not already discussed include possible underascertainment of thyroid cancer cases, particularly for patients who moved out of state after transplantation. However, we expect this bias to be small, considering that only 6% of transplant recipients no longer resided in their initial state or region 10 years after transplantation (7). We lacked information on dose and changes in immunosuppressant medications received by transplantation recipients, which limited our assessment of the effects of these medications on thyroid cancer risk. We note that some subgroups of transplant recipients had few cancer cases, and that wide confidence intervals for some IRRs convey uncertainty regarding the associations. Also, our results were not adjusted for multiple comparisons, and some findings may be due to chance alone.
In summary, our findings indicate that the elevated incidence of thyroid cancer among transplant recipients may not be explained entirely by heightened surveillance and overdiagnosis. We found that hypertensive nephrosclerosis as an indication for kidney transplantation and longer duration of prior dialysis were each associated with a higher incidence of thyroid cancer among kidney recipients, suggesting that the metabolic or endocrine effects of kidney disease and factors associated with longer duration on dialysis (5+ years) may contribute to thyroid carcinogenesis. Thyroid cancer incidence was also increased among liver recipients whose indication for transplantation was cholestatic liver disease/cirrhosis, which may provide further etiologic clues.
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